AstraZeneca Opens Drug Library To Malaria Researchers
28th Jun 2010 14:54
LONDON (Dow Jones)--U.K. drug maker AstraZeneca PLC (AZN.LN) said Monday it is giving researchers access to 500,000 compounds in its library in a drive to find new drugs for malaria. AstraZeneca said it entered an alliance with Medicines for Malaria Venture, a not-for-profit foundation set up to
Read moreStudies Show Potential Of New Type Of Diabetes Drug
26th Jun 2010 21:26
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES ORLANDO, Fla. (Dow Jones)--A new class of drugs being developed to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies released at a majo
Read moreStudies Show Potential Of New Type Of Diabetes Drug
26th Jun 2010 21:26
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES ORLANDO, Fla. (Dow Jones)--A new class of drugs being developed to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies released at a majo
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To -2-
26th Jun 2010 19:45
on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutic
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control in Patients With Type 2 Diabetes Inadequately Controlled With Insulin
26th Jun 2010 19:45
ORLANDO, Fla.--(BUSINESS WIRE)--June 26, 2010-- Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes pa
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To -2-
26th Jun 2010 19:45
Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, d
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
26th Jun 2010 19:45
/NOT FOR US MEDIA/ ORLANDO, FL, June 26 /CNW/ - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes p
Read morePRESS RELEASE: 52-Week Study Finds ONGLYZA(TM) -2-
26th Jun 2010 15:00
Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improvin
Read morePRESS RELEASE: 52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added to Metformin Was Non-Inferior to Titrated Glipizide When Added to Metformin in Reducing Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
26th Jun 2010 15:00
ORLANDO--(BUSINESS WIRE)--June 26, 2010-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found th
Read morePRESS RELEASE: ONGLYZA(TM) (saxagliptin) With -2-
26th Jun 2010 14:30
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews
Read morePRESS RELEASE: ONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control in Treatment-Naive Adults With Type 2 Diabetes
26th Jun 2010 14:30
ORLANDO, Fla.--(BUSINESS WIRE)--June 26, 2010-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improveme
Read moreLondon midday: Stormy weather for BP
25th Jun 2010 12:01
Mining stocks and BP have combined to spoil what was a firm start by London's blue-chip stocks, with even the weather now appearing to have it in for the beleaguered UK oil giant. Mining stocks such as ENRC, Lonmin and Kazkhmys suffer chunky falls but these are dwarfed by BP shares, which are havin
Read moreEU Panel Adopts Positive Opinion On Vpriv From Shire
25th Jun 2010 10:33
LONDON (Dow Jones)--The Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion on Vpriv (velaglucerase alfa), from Shire Pharmaceutical Ireland Ltd, an orphan medicine intended for the treatment of Gaucher disease adding that Vpriv might constitute an
Read moreLondon open: Healthy start for blue chips
25th Jun 2010 08:56
London has shrugged off Dow Jones' triple-digit fall overnight and made decent headway this morning. Banks are higher after a jam-packed financial stability report from the Bank of England that covered everything from savings ratios to the threat of the eurozone. The market sems to have focused on
Read moreAstraZeneca Buys Back 300,000 Shares At 2985P
25th Jun 2010 08:00
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Friday it has purchased for cancellation 300,000 of its ordinary shares at a price of 2985 pence per share. MAIN FACTS: -Shares closed Thursday at 2997 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-9268; tommy.stubbington
Read more